- Home
- STHO vs CRBP Comparison
STHO vs CRBP Comparison
Compare STHO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- CRBP
- Stock Information
- Founded
- STHO N/A
- CRBP 2009
- Country
- STHO United States
- CRBP United States
- Employees
- STHO N/A
- CRBP N/A
- Industry
- STHO Real Estate
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- STHO Real Estate
- CRBP Health Care
- Exchange
- STHO Nasdaq
- CRBP Nasdaq
- Market Cap
- STHO 120.0M
- CRBP 143.7M
- IPO Year
- STHO N/A
- CRBP N/A
- Fundamental
- Price
- STHO $9.01
- CRBP $11.93
- Analyst Decision
- STHO
- CRBP Strong Buy
- Analyst Count
- STHO 0
- CRBP 8
- Target Price
- STHO N/A
- CRBP $62.00
- AVG Volume (30 Days)
- STHO 95.2K
- CRBP 256.8K
- Earning Date
- STHO 02-25-2025
- CRBP 03-11-2025
- Dividend Yield
- STHO N/A
- CRBP N/A
- EPS Growth
- STHO N/A
- CRBP N/A
- EPS
- STHO 6.15
- CRBP N/A
- Revenue
- STHO $117,752,000.00
- CRBP N/A
- Revenue This Year
- STHO N/A
- CRBP N/A
- Revenue Next Year
- STHO N/A
- CRBP N/A
- P/E Ratio
- STHO $1.47
- CRBP N/A
- Revenue Growth
- STHO 13.35
- CRBP N/A
- 52 Week Low
- STHO $8.26
- CRBP $7.30
- 52 Week High
- STHO $14.50
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- STHO 37.20
- CRBP 39.08
- Support Level
- STHO $8.85
- CRBP $11.02
- Resistance Level
- STHO $9.08
- CRBP $13.28
- Average True Range (ATR)
- STHO 0.27
- CRBP 0.74
- MACD
- STHO 0.07
- CRBP 0.16
- Stochastic Oscillator
- STHO 46.58
- CRBP 40.27
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.